论文部分内容阅读
1例64岁女性子宫内膜癌患者化疗前为防止紫杉醇过敏反应，予以地塞米松磷酸钠注射液10 mg入5%葡萄糖注射液100 ml静脉滴注，约30 min滴注完毕，输注过程中患者无不适。约2 h后，患者出现尿失禁，无尿急、尿痛，此后逐渐缓解。患者第2次静脉滴注地塞米松磷酸钠注射液后2 h，尿失禁症状复现。将静脉滴注地塞米松磷酸钠注射液改为口服地塞米松片后尿失禁症状减轻。考虑患者的暂时性尿失禁很可能与地塞米松磷酸钠有关。“,”A 64-year-old female patient with endometrial cancer received an IV infusion of dexamethasone sodium phosphate injection 10 mg dissolved in 5% glucose injection 100 ml before chemotherapy to prevent allergic reaction induced by paclitaxel. The infusion was finished within about 30 minutes and the patient had no discomfort during the infusion. About 2 hours later, the patient developed urinary incontinence without urgent and painful urination, which gradually disappeared. Two hours after the second intravenous infusion of dexamethasone sodium phosphate injection, urinary incontinence recurred. After the intravenous infusion of dexamethasone sodium phosphate injection was replaced by oral dexamethasone tablets, the symptoms of urinary incontinence were alleviated. It was considered that the temporary urinary incontinence was probably related to dexamethasone sodium phosphate.